Olezarsen, an antisense oligonucleotide that targets the mRNA for apolipoprotein C-III, reduced triglycerides (TGs) in patients with severe hypertriglyceridemia (sHTG, TG >500 mg/dL) by 50-72% at 6 months in two double-blinded placebo-controlled randomized clinical trials (RCTs, CORE-TIMI 72a, CORE2-TIMI 72b)....
R. Giugliano, N. Marston, B. Bergmark et al.· European Heart Journal· 0 citations
Olezarsen reduced triglycerides across the hypertriglyceridemia spectrum, with greater effects in patients on background fibrates, particularly with diabetes, to support potential complementary mechanisms and further investigation of concomitant triglyceride-reducing therapy.
Annabel Z. Wang, V. Alexander, T. Prohaska et al.· Journal of Clinical Lipidolo...· 1 citation
Extracranial clinically relevant bleeding is common among patients with AF treated with OACs and may more accurately reflect the overall burden of bleeding than major bleeding alone, suggesting that additional unmeasured or unknown factors contribute to bleeding risk.
Deborah M. Siegal, Marc Carrier, M. Bahit et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.